CammieBeo personal page - To The Moon

CammieBeo

CammieBeo

No personal profile

11Follow

1Followers

0Topic

0Badge

2021-08-26

How does Pubmatic compare with Magnite?

Sorry, the original content has been removed

2021-08-17

Buy more on drop

Sorry, the original content has been removed

2021-08-10

Woww

Sorry, the original content has been removed

2021-08-10

Wowww

Here's Who's Making a $1 Billion Bet on Moderna

2021-08-01

Incredible! Watch and see

Investors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year

2021-07-20

Why pfizer price never increase much, unlike moderna?

3 Areas Where Pfizer Is Crushing Moderna

2021-07-17

Uh oh is a crash coming

3 Moves You'll Sorely Regret in a Stock Market Crash

2021-07-17

Goody

Sorry, the original content has been removed

2021-07-17

Nice

Sorry, the original content has been removed

2021-07-14

Time to accumulate

Don’t Worry, ContextLogic’s Story Hasn’t Been Fully Written Yet

2021-07-13

Batteries!

Sorry, the original content has been removed

2021-07-12

Space travel, anyone?

Virgin Galactic fell 6% in the morning trading, as once rising more than 10% in premarket trading.

2021-07-10

Wow

Sorry, the original content has been removed

2021-07-09

Great ariticle, would you like to share it?

Sorry, the original content has been removed

2021-07-09

Uh oh

Tesla Shares Form Death Cross, Portending Further Declines

2021-07-09

Buy one?

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3565492638324481,"uuid":"3565492638324481","gmtCreate":1602400857711,"gmtModify":1625494942993,"name":"CammieBeo","pinyin":"cammiebeo","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":11,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.12","exceedPercentage":"93.17%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":810826197,"gmtCreate":1629964672519,"gmtModify":1676530186011,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"How does Pubmatic compare with Magnite?","listText":"How does Pubmatic compare with Magnite?","text":"How does Pubmatic compare with Magnite?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810826197","repostId":"2161742695","repostType":4,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833345858,"gmtCreate":1629208023174,"gmtModify":1676529966304,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy more on drop&nbsp;","listText":"Buy more on drop&nbsp;","text":"Buy more on drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833345858","repostId":"1113768464","repostType":2,"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896734787,"gmtCreate":1628604846549,"gmtModify":1676529794928,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Woww","listText":"Woww","text":"Woww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896734787","repostId":"2158048475","repostType":4,"isVote":1,"tweetType":1,"viewCount":159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896734208,"gmtCreate":1628604826404,"gmtModify":1676529794920,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wowww","listText":"Wowww","text":"Wowww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896734208","repostId":"2158048475","repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://www.laohu8.com/m/news/2158048475?lang=&edition=full","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802541302,"gmtCreate":1627790858006,"gmtModify":1703495936888,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Incredible! Watch and see","listText":"Incredible! Watch and see","text":"Incredible! Watch and see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/802541302","repostId":"1142925544","repostType":4,"repost":{"id":"1142925544","pubTimestamp":1627787240,"share":"https://www.laohu8.com/m/news/1142925544?lang=&edition=full","pubTime":"2021-08-01 11:07","market":"us","language":"en","title":"Investors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1142925544","media":"Barron's","summary":"“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970","content":"<p>“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970s, recalling pleasant times at the beach or by the barbecue. No need to remind anyone back then of droughts, wildfires, or Covid-19 surges that are unfortunate features of the steamy season this year.</p>\n<p>But the coming of August also means entering what historically has been the most treacherous stretch of the year for stocks, according to data going back to 1928 compiled by Bank of America analyst Stephen Suttmeier. He finds that theS&amp;P 500index had a negative return averaging 0.03% in August, September, and October—the worst three-month span of the year for the big-cap benchmark. In fact, they constitute the only three-month period that averages in the red.</p>\n<p>August actually is bracketed by the best and worst months of the year, he adds in a research note. July averages a 1.58% return on the S&amp;P 500, with positive results 59.1% of the time, while September averages a negative 1.03%, ending in the plus column less than half of the time, or 45%.</p>\n<p>This July did even better than the norm, with the S&amp;P 500 gaining 2.27%. It also was the sixth consecutive up month for the index—the longest positive streak since September 2018, according to Dow Jones’ statistical mavens. During that period, its cumulative advance was 18.34%.</p>\n<p>August’s record is in between, with an average 0.70% S&amp;P 500 return and positive results 58.1% of the time, marking a transition from the “summer rip” to the “fall dip.”</p>\n<p>Not surprisingly, the laggard returns of the August-October period are accompanied by an uptick in volatility, Suttmeier finds. Based on records going back to 1992, theCboe Volatility Index,or VIX, has often seen spikes during those months, following relatively subdued volatility in the April-July period.</p>\n<p>Past isn’t necessarily prologue, but if it is, the timing of the initial public offering byRobinhood Markets(ticker: HOOD) might prove propitious, if the stock market does have its typical seasonal rough patch. The online broker, whose putative mission is to open investing to novices supposedly ignored by established outfits, sold 55 million shares at $38 on Thursday. In the process, it provided a valuable lesson to all those who got in on the IPO: Buy low and sell high.</p>\n<p>The company evidently fulfilled the latter imperative, selling its shares high, even though they were priced at the low end of the expected $38-$42 range. Their price sank 8.4% on their first day of trading, although they recouped a bit on Friday. By week’s end, buyers of Robinhood’s IPO who held were down 7.5%.</p>\n<p>Among those who sold high were the company’s co-founders, CEO Vladimir Tenev and Chief Creative Officer Baiju Bhatt, who each offloaded 1.25 million shares in the IPO. As my illustrious predecessor, Alan Abelson, liked to observe, there are many good reasons to sell a stock, but expecting it to go up isn’t one of them. That has never been more true, given the ability of rich owners to monetize their assets by borrowing against them cheaply, and without incurring capital-gains taxes.</p>\n<p>To be sure, Tenev and Bhatt still have significant stakes in Robinhood. Asour colleague Avi Salzman reported, these were worth $2.5 billion at the initial offering price, and Tenev and Bhatt retain voting control. The two also could receive awards of shares worth as much as $6.7 billion for Tenev and $4 billion for Bhatt, if the stock hits $300, or nearly the proverbial ten-bagger from here.</p>\n<p>But in a blow against income inequality, the potential billionaire pair took symbolic pay cuts, to $34,248, the average annual wage of American workers. As the comedian Yakov Smirnoff likes to say, “What a country!”</p>\n<p>How those workers are faring will be a subject of the monthly employment report slated for release this coming Friday.</p>\n<p>Economists’ forecasts for nonfarm payrolls center around a gain of 900,000. Jefferies economists Aneta Markowska and Thomas Simons estimate that the increase could top the long-anticipated one million mark; they forecast 1.2 million.</p>\n<p>Markowska and Simons think the expiration of supplemental unemployment benefits in some states will boost the labor supply, although that is a matter of significant debate. (For more on the jobs market, seethis week’s cover story.)</p>\n<p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-01 11:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-news-robinhood-sp500-51627692215?mod=hp_LATEST><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970s, recalling pleasant times at the beach or by the barbecue. No need to remind anyone back then of ...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-news-robinhood-sp500-51627692215?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.barrons.com/articles/stocks-news-robinhood-sp500-51627692215?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142925544","content_text":"“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970s, recalling pleasant times at the beach or by the barbecue. No need to remind anyone back then of droughts, wildfires, or Covid-19 surges that are unfortunate features of the steamy season this year.\nBut the coming of August also means entering what historically has been the most treacherous stretch of the year for stocks, according to data going back to 1928 compiled by Bank of America analyst Stephen Suttmeier. He finds that theS&P 500index had a negative return averaging 0.03% in August, September, and October—the worst three-month span of the year for the big-cap benchmark. In fact, they constitute the only three-month period that averages in the red.\nAugust actually is bracketed by the best and worst months of the year, he adds in a research note. July averages a 1.58% return on the S&P 500, with positive results 59.1% of the time, while September averages a negative 1.03%, ending in the plus column less than half of the time, or 45%.\nThis July did even better than the norm, with the S&P 500 gaining 2.27%. It also was the sixth consecutive up month for the index—the longest positive streak since September 2018, according to Dow Jones’ statistical mavens. During that period, its cumulative advance was 18.34%.\nAugust’s record is in between, with an average 0.70% S&P 500 return and positive results 58.1% of the time, marking a transition from the “summer rip” to the “fall dip.”\nNot surprisingly, the laggard returns of the August-October period are accompanied by an uptick in volatility, Suttmeier finds. Based on records going back to 1992, theCboe Volatility Index,or VIX, has often seen spikes during those months, following relatively subdued volatility in the April-July period.\nPast isn’t necessarily prologue, but if it is, the timing of the initial public offering byRobinhood Markets(ticker: HOOD) might prove propitious, if the stock market does have its typical seasonal rough patch. The online broker, whose putative mission is to open investing to novices supposedly ignored by established outfits, sold 55 million shares at $38 on Thursday. In the process, it provided a valuable lesson to all those who got in on the IPO: Buy low and sell high.\nThe company evidently fulfilled the latter imperative, selling its shares high, even though they were priced at the low end of the expected $38-$42 range. Their price sank 8.4% on their first day of trading, although they recouped a bit on Friday. By week’s end, buyers of Robinhood’s IPO who held were down 7.5%.\nAmong those who sold high were the company’s co-founders, CEO Vladimir Tenev and Chief Creative Officer Baiju Bhatt, who each offloaded 1.25 million shares in the IPO. As my illustrious predecessor, Alan Abelson, liked to observe, there are many good reasons to sell a stock, but expecting it to go up isn’t one of them. That has never been more true, given the ability of rich owners to monetize their assets by borrowing against them cheaply, and without incurring capital-gains taxes.\nTo be sure, Tenev and Bhatt still have significant stakes in Robinhood. Asour colleague Avi Salzman reported, these were worth $2.5 billion at the initial offering price, and Tenev and Bhatt retain voting control. The two also could receive awards of shares worth as much as $6.7 billion for Tenev and $4 billion for Bhatt, if the stock hits $300, or nearly the proverbial ten-bagger from here.\nBut in a blow against income inequality, the potential billionaire pair took symbolic pay cuts, to $34,248, the average annual wage of American workers. As the comedian Yakov Smirnoff likes to say, “What a country!”\nHow those workers are faring will be a subject of the monthly employment report slated for release this coming Friday.\nEconomists’ forecasts for nonfarm payrolls center around a gain of 900,000. Jefferies economists Aneta Markowska and Thomas Simons estimate that the increase could top the long-anticipated one million mark; they forecast 1.2 million.\nMarkowska and Simons think the expiration of supplemental unemployment benefits in some states will boost the labor supply, although that is a matter of significant debate. (For more on the jobs market, seethis week’s cover story.)","news_type":1},"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178171901,"gmtCreate":1626794263303,"gmtModify":1703765401659,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Why pfizer price never increase much, unlike moderna?","listText":"Why pfizer price never increase much, unlike moderna?","text":"Why pfizer price never increase much, unlike moderna?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/178171901","repostId":"2152405667","repostType":4,"repost":{"id":"2152405667","pubTimestamp":1626790080,"share":"https://www.laohu8.com/m/news/2152405667?lang=&edition=full","pubTime":"2021-07-20 22:08","market":"us","language":"en","title":"3 Areas Where Pfizer Is Crushing Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2152405667","media":"Motley Fool","summary":"They could result in a broader market for Pfizer's vaccine.","content":"<p><b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> </b>and <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> have been marching in lockstep for nearly a year. They both announced the start of phase 3 trials for their coronavirus vaccine candidates on the same day last July. Pfizer won Emergency Use Authorization for its vaccine only about a week ahead of Moderna. And the U.S. ordered 300 million doses from each company earlier in the year. That was enough to vaccinate almost the entire population.</p>\n<p>It's fair to say both of these companies today are leading the coronavirus vaccine market. Still, Pfizer has inched ahead in a couple of ways. It has fully vaccinated more Americans than Moderna so far. And recently, it scored an order for as many as 1.8 billion doses from the European Union through 2023. That's in addition to an earlier order. But that's not all. There are three other areas where Pfizer is beating Moderna...</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F634091%2Fgettyimages-surprised-business-person.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. The path to full approval</h3>\n<p>Pfizer and partner <b>BioNTech</b> said last week the U.S. Food and Drug Administration granted their vaccine priority review. The agency's standard review time usually takes between six to 10 months. Priority review takes a maximum of six. So, in this case, the agency's deadline to make an approval decision is in January. In even better news, an FDA official told CNN that regulators may issue a decision in as little as two months.</p>\n<p>Where does Moderna stand? The biotech submitted its request for approval a month behind Pfizer. Moderna also requested priority review. If all goes smoothly for Moderna, it may follow in Pfizer's footsteps. And in this case, we might expect a regulatory decision about a month after the Pfizer decision. If any issues arise, of course, Moderna could fall behind.</p>\n<h3>2. The booster plan</h3>\n<p>Pfizer and Moderna announced work on boosters to address variants earlier this year. Both companies are studying variant-specific candidates as well as an extra dose of their vaccines. But Pfizer made the study of a third vaccine dose the priority. And the company recently said it will ask for regulatory authorization of that dose in the coming weeks. Meanwhile, it plans to begin clinical trials of a variant-specific version of its vaccine in August.</p>\n<p>Moderna simultaneously started clinical trials of three candidates: an extra dose of vaccine, a strain-specific candidate, and a combination of its vaccine and the strain-specific candidate. The company has said it will have a booster ready by fall.</p>\n<p>If Pfizer stays on track, it looks like it will make it to market ahead of Moderna though. Pfizer's data are ready for regulators -- and it may be easier to win authorization for another dose of a vaccine that's already been given to millions of people than a new candidate.</p>\n<h3>3. Back-to-school vaccinations</h3>\n<p>Regulators in the U.S. and Europe authorized Pfizer's vaccine in teens 12 through 15 back in May. The original authorization includes individuals ages 16 and older. The company reported positive trial data on March 31.</p>\n<p>Moderna announced positive results from its teen study in late May -- and the company applied for authorization in the U.S. and Europe about two weeks later. Regulatory decisions may come any day now. But Pfizer has a clear advantage. Its vaccine got the OK before teens headed off to summer activities or vacation. And that's likely when a lot of teens would opt for vaccination to be fully protected before school starts. Pfizer and Moderna vaccines require two doses about a month apart.</p>\n<h3>What does all of this mean for investors?</h3>\n<p>These points are good news for Pfizer. A fully approved vaccine likely will attract many individuals who hesitated to go for an experimental product. So, if the FDA gives a nod, more and more people may request a Pfizer jab. A quicker-to-market booster and an authorization for teens also mean more individuals may go for a Pfizer shot in the near term.</p>\n<p>But none of these points will immediately equal more revenue for Pfizer. Governments already have purchased doses. If Pfizer <i>stays </i>ahead of Moderna on each of the above points, though, these doses may be used up faster than planned. And that may mean more orders down the road. And therefore, more revenue. The first-to-market status also may keep governments coming back for more of the same -- so Pfizer may attract bigger orders.</p>\n<p>All is not lost for Moderna though. Far from it. Yes, Pfizer is dominating in the above areas. And that may even continue. But Moderna isn't far behind. As we've seen so far, there's room for more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> player in this market. Pfizer expects $26 billion in vaccine revenue this year. And Moderna's advance purchase orders total $19.2 billion so far. Both already are winning orders for 2022.</p>\n<p>This means an investment in either of these coronavirus vaccine leaders today is likely to pay off now -- and in the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Areas Where Pfizer Is Crushing Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Areas Where Pfizer Is Crushing Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/20/3-areas-where-pfizer-is-crushing-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer and Moderna, Inc. have been marching in lockstep for nearly a year. They both announced the start of phase 3 trials for their coronavirus vaccine candidates on the same day last July. Pfizer ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/20/3-areas-where-pfizer-is-crushing-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/20/3-areas-where-pfizer-is-crushing-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152405667","content_text":"Pfizer and Moderna, Inc. have been marching in lockstep for nearly a year. They both announced the start of phase 3 trials for their coronavirus vaccine candidates on the same day last July. Pfizer won Emergency Use Authorization for its vaccine only about a week ahead of Moderna. And the U.S. ordered 300 million doses from each company earlier in the year. That was enough to vaccinate almost the entire population.\nIt's fair to say both of these companies today are leading the coronavirus vaccine market. Still, Pfizer has inched ahead in a couple of ways. It has fully vaccinated more Americans than Moderna so far. And recently, it scored an order for as many as 1.8 billion doses from the European Union through 2023. That's in addition to an earlier order. But that's not all. There are three other areas where Pfizer is beating Moderna...\n\nImage source: Getty Images.\n1. The path to full approval\nPfizer and partner BioNTech said last week the U.S. Food and Drug Administration granted their vaccine priority review. The agency's standard review time usually takes between six to 10 months. Priority review takes a maximum of six. So, in this case, the agency's deadline to make an approval decision is in January. In even better news, an FDA official told CNN that regulators may issue a decision in as little as two months.\nWhere does Moderna stand? The biotech submitted its request for approval a month behind Pfizer. Moderna also requested priority review. If all goes smoothly for Moderna, it may follow in Pfizer's footsteps. And in this case, we might expect a regulatory decision about a month after the Pfizer decision. If any issues arise, of course, Moderna could fall behind.\n2. The booster plan\nPfizer and Moderna announced work on boosters to address variants earlier this year. Both companies are studying variant-specific candidates as well as an extra dose of their vaccines. But Pfizer made the study of a third vaccine dose the priority. And the company recently said it will ask for regulatory authorization of that dose in the coming weeks. Meanwhile, it plans to begin clinical trials of a variant-specific version of its vaccine in August.\nModerna simultaneously started clinical trials of three candidates: an extra dose of vaccine, a strain-specific candidate, and a combination of its vaccine and the strain-specific candidate. The company has said it will have a booster ready by fall.\nIf Pfizer stays on track, it looks like it will make it to market ahead of Moderna though. Pfizer's data are ready for regulators -- and it may be easier to win authorization for another dose of a vaccine that's already been given to millions of people than a new candidate.\n3. Back-to-school vaccinations\nRegulators in the U.S. and Europe authorized Pfizer's vaccine in teens 12 through 15 back in May. The original authorization includes individuals ages 16 and older. The company reported positive trial data on March 31.\nModerna announced positive results from its teen study in late May -- and the company applied for authorization in the U.S. and Europe about two weeks later. Regulatory decisions may come any day now. But Pfizer has a clear advantage. Its vaccine got the OK before teens headed off to summer activities or vacation. And that's likely when a lot of teens would opt for vaccination to be fully protected before school starts. Pfizer and Moderna vaccines require two doses about a month apart.\nWhat does all of this mean for investors?\nThese points are good news for Pfizer. A fully approved vaccine likely will attract many individuals who hesitated to go for an experimental product. So, if the FDA gives a nod, more and more people may request a Pfizer jab. A quicker-to-market booster and an authorization for teens also mean more individuals may go for a Pfizer shot in the near term.\nBut none of these points will immediately equal more revenue for Pfizer. Governments already have purchased doses. If Pfizer stays ahead of Moderna on each of the above points, though, these doses may be used up faster than planned. And that may mean more orders down the road. And therefore, more revenue. The first-to-market status also may keep governments coming back for more of the same -- so Pfizer may attract bigger orders.\nAll is not lost for Moderna though. Far from it. Yes, Pfizer is dominating in the above areas. And that may even continue. But Moderna isn't far behind. As we've seen so far, there's room for more than one player in this market. Pfizer expects $26 billion in vaccine revenue this year. And Moderna's advance purchase orders total $19.2 billion so far. Both already are winning orders for 2022.\nThis means an investment in either of these coronavirus vaccine leaders today is likely to pay off now -- and in the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179226240,"gmtCreate":1626536726780,"gmtModify":1703761558606,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Uh oh is a crash coming","listText":"Uh oh is a crash coming","text":"Uh oh is a crash coming","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/179226240","repostId":"2152899486","repostType":4,"repost":{"id":"2152899486","pubTimestamp":1626530220,"share":"https://www.laohu8.com/m/news/2152899486?lang=&edition=full","pubTime":"2021-07-17 21:57","market":"us","language":"en","title":"3 Moves You'll Sorely Regret in a Stock Market Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2152899486","media":"Motley Fool","summary":"A market downturn could happen when you least expect it. Don't make these mistakes when the next one hits.","content":"<p>The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be terrifying for investors who aren't used to them.</p>\n<p>But the decisions you make during a market crash will dictate whether you survive it unscathed, or whether you end up taking serious losses you don't recover from for years. With that in mind, here are three moves you might seriously regret during a stock market downturn.</p>\n<h2>1. Selling when investment values plunge</h2>\n<p>When you buy stocks, you lock in those investments at a certain price. That price can then rise or fall on an ongoing basis.</p>\n<p>If you don't sell your stocks while their value is up, you won't make money. Similarly, if you don't sell your stocks when their values declines, you won't suffer losses. It's the latter you really need to keep in mind during a stock market crash.</p>\n<p>When investment values start to fall, it can very tempting to cash out investments in an effort to minimize the blow. But the stock market has a long history of recovering from crashes, so if you leave your portfolio alone, you'll give your stock values a chance to come back up rather than guarantee yourself losses that could've been easily avoided.</p>\n<h2>2. Pausing your retirement plan contributions</h2>\n<p>The point of putting money into a 401(k) or IRA isn't to just let it sit there in cash. Rather, you're supposed to invest it so it grows into a large sum over time.</p>\n<p>You may be inclined to stop funding your retirement savings during periods when the stock market is doing poorly. But that's a mistake. The money that goes into your retirement plan gets tax-advantaged treatment, whether immediately or in the future, so it pays to keep pumping cash into your account even when the stock market isn't at its strongest.</p>\n<h2>3. Not adding discounted stocks to your portfolio</h2>\n<p>Many people assume that buying stocks during a market crash is a bad idea. But actually, the opposite is true.</p>\n<p>During market downturns, stock values tend to fall across the board. But that doesn't necessarily mean that the companies you're interested in are actually worth less money than they were the month prior. It just means that temporarily, their share prices are down. That gives you a prime opportunity to buy quality stocks when they're less expensive.</p>\n<p>For example, if you're interested in a given company whose share prices has been hovering around $50, during a market crash, it might fall to $40. Does that mean that from now on, shares will only be worth 40? Not at all. But if you scoop them up at $40 apiece, you'll set yourself up to profit big time when their values creeps back up to $50 or beyond.</p>\n<p>Knowing how to navigate a stock market crash could prevent you from making poor decisions that hurt you financially. Avoid the above mistakes the next time the market takes a turn for the worse -- you'll be much better off for it in the long run.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Moves You'll Sorely Regret in a Stock Market Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Moves You'll Sorely Regret in a Stock Market Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-17 21:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152899486","content_text":"The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be terrifying for investors who aren't used to them.\nBut the decisions you make during a market crash will dictate whether you survive it unscathed, or whether you end up taking serious losses you don't recover from for years. With that in mind, here are three moves you might seriously regret during a stock market downturn.\n1. Selling when investment values plunge\nWhen you buy stocks, you lock in those investments at a certain price. That price can then rise or fall on an ongoing basis.\nIf you don't sell your stocks while their value is up, you won't make money. Similarly, if you don't sell your stocks when their values declines, you won't suffer losses. It's the latter you really need to keep in mind during a stock market crash.\nWhen investment values start to fall, it can very tempting to cash out investments in an effort to minimize the blow. But the stock market has a long history of recovering from crashes, so if you leave your portfolio alone, you'll give your stock values a chance to come back up rather than guarantee yourself losses that could've been easily avoided.\n2. Pausing your retirement plan contributions\nThe point of putting money into a 401(k) or IRA isn't to just let it sit there in cash. Rather, you're supposed to invest it so it grows into a large sum over time.\nYou may be inclined to stop funding your retirement savings during periods when the stock market is doing poorly. But that's a mistake. The money that goes into your retirement plan gets tax-advantaged treatment, whether immediately or in the future, so it pays to keep pumping cash into your account even when the stock market isn't at its strongest.\n3. Not adding discounted stocks to your portfolio\nMany people assume that buying stocks during a market crash is a bad idea. But actually, the opposite is true.\nDuring market downturns, stock values tend to fall across the board. But that doesn't necessarily mean that the companies you're interested in are actually worth less money than they were the month prior. It just means that temporarily, their share prices are down. That gives you a prime opportunity to buy quality stocks when they're less expensive.\nFor example, if you're interested in a given company whose share prices has been hovering around $50, during a market crash, it might fall to $40. Does that mean that from now on, shares will only be worth 40? Not at all. But if you scoop them up at $40 apiece, you'll set yourself up to profit big time when their values creeps back up to $50 or beyond.\nKnowing how to navigate a stock market crash could prevent you from making poor decisions that hurt you financially. Avoid the above mistakes the next time the market takes a turn for the worse -- you'll be much better off for it in the long run.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179221805,"gmtCreate":1626536508707,"gmtModify":1703761555694,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Goody&nbsp;","listText":"Goody&nbsp;","text":"Goody","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/179221805","repostId":"2152894306","repostType":2,"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170786898,"gmtCreate":1626451412314,"gmtModify":1703760536573,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170786898","repostId":"1149577900","repostType":4,"isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144192413,"gmtCreate":1626270899732,"gmtModify":1703756786220,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to accumulate","listText":"Time to accumulate","text":"Time to accumulate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/144192413","repostId":"1164055885","repostType":2,"repost":{"id":"1164055885","pubTimestamp":1626141384,"share":"https://www.laohu8.com/m/news/1164055885?lang=&edition=full","pubTime":"2021-07-13 09:56","market":"us","language":"en","title":"Don’t Worry, ContextLogic’s Story Hasn’t Been Fully Written Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164055885","media":"InvestorPlace","summary":"But the next chapter could very well include massive progress and success for WISH stock.\n\nThere’s n","content":"<blockquote>\n But the next chapter could very well include massive progress and success for WISH stock.\n</blockquote>\n<p>There’s no denying it. Times have been tough lately for investors of mobile commerce company<b>ContextLogic</b>&nbsp;(NASDAQ:<b><u>WISH</u></b>). Since the company’s initial public offering (IPO), WISH stock hasn’t held up particularly well.</p>\n<p><img src=\"https://static.tigerbbs.com/533f4f73a24408dca732699e9657eab7\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: sdx15 / Shutterstock.com</p>\n<p>I won’t try to paint a rosy picture here. It’s a challenging situation if you’re an early investor.</p>\n<p>Yet, perhaps it’s now possible to add to your position at a more favorable price point, or start a new position if you’re not already invested.</p>\n<p>Besides, there’s favorable news to boost your spirits if you’re bullish on ContextLogic. In fact, there’s a value-added partnership in the works — along with a regulatory development that could advance the company’s geographic reach.</p>\n<p><b>A Closer Look at WISH Stock</b></p>\n<p>Let’s go back to the beginning, which actually wasn’t very long ago.</p>\n<p>After ContextLogicset a price rangeof $22 to $24 for its IPO, the company sold 46 million shares of WISH stock at $24 apiece on Dec. 15, 2020.</p>\n<p>Everything was off to a good start, or so it seemed. A brief rally ensued, with ContextLogic shares climbing to a 52-week high of $32.85 on Feb. 1, 2021. The situation turned sour after that, however. As it turned out, WISH stock sank during the following months, and even fell below $8 in June.</p>\n<p>There might be a dip-buying opportunity here, though — and the potential for a comeback. As of July 12, the ContextLogic share price was already over $11.</p>\n<p>In the interest of full disclosure, I feel compelled to reveal this: on a trailing-12-month basis, ContextLogic has -$3.16 in earnings per share. That’s not great news, but it’s not hopeless. Without a doubt, the stakeholders will want to see that number turn positive in the near future.</p>\n<p><b>A License to Sell</b></p>\n<p>The Wish platform is supposed to be a place where shoppers on multiple continents can purchase a wide variety of products online. And judging by some recently reported data, Wish’s global e-commerce ambitions are panning out quite well.</p>\n<p>ContextLogic reported that its Core Marketplace segment’s first-quarter 2021 revenuesincreased by 40%year-over-year. Furthermore, looking at the bigger picture, the company’s total revenues for 2021’s first quarter showed a massive 75% year-over-year improvement.</p>\n<p>That alone should convince the skeptics to change their minds. Yet, there’s even more good news to share.</p>\n<p>On July 6, ContextLogic revealed that the Dutch Central Bank hadgranted the companya Payment Services License for the European Union.</p>\n<p>Apparently, this license will enable Wish to increase the company’s control over the payments value chain in a compliant manner. At the same time, it should allow Wish to reduce its reliance on third parties.</p>\n<p>This has vast geographic implications, as, in addition to the Netherlands, the license “will be passported to the other European markets where Wish operates.”</p>\n<p><b>Expanding Its Reach</b></p>\n<p>On top of all that, ContextLogic has disclosed a collaboration with another prominent e-commerce platform.</p>\n<p>This could be a real game changer.</p>\n<p>According to a press release, ContextLogicannounced a two-year partnershipwith<b>PrestaShop</b>in which “more than 300,000 merchants and brands on the PrestaShop platform will be able to quickly and easily sell to millions of consumers on the Wish marketplace.”</p>\n<p>The PrestShop platform operates in Europe and Latin America. So once again, we’re bearing witness to ContextLogic’s rapid expansion into the EU and, ultimately, around the world.</p>\n<p>Alan Small, senior business development manager for Wish in Europe, expressed his company’s ambitious vision with the PrestaShop partnership; “Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on,” Small explained.</p>\n<p><b>The Bottom Line</b></p>\n<p>Okay, so WISH stock hasn’t been a blockbuster success since its IPO.</p>\n<p>However, the story hasn’t been fully written yet.</p>\n<p>And, the next few chapters could involve ContextLogic’s rapid progress — not only in the European market, but globally.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Don’t Worry, ContextLogic’s Story Hasn’t Been Fully Written Yet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDon’t Worry, ContextLogic’s Story Hasn’t Been Fully Written Yet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-13 09:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/wish-stock-contextlogics-story-hasnt-been-fully-written-yet/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>But the next chapter could very well include massive progress and success for WISH stock.\n\nThere’s no denying it. Times have been tough lately for investors of mobile commerce companyContextLogic (...</p>\n\n<a href=\"https://investorplace.com/2021/07/wish-stock-contextlogics-story-hasnt-been-fully-written-yet/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/07/wish-stock-contextlogics-story-hasnt-been-fully-written-yet/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164055885","content_text":"But the next chapter could very well include massive progress and success for WISH stock.\n\nThere’s no denying it. Times have been tough lately for investors of mobile commerce companyContextLogic (NASDAQ:WISH). Since the company’s initial public offering (IPO), WISH stock hasn’t held up particularly well.\nSource: sdx15 / Shutterstock.com\nI won’t try to paint a rosy picture here. It’s a challenging situation if you’re an early investor.\nYet, perhaps it’s now possible to add to your position at a more favorable price point, or start a new position if you’re not already invested.\nBesides, there’s favorable news to boost your spirits if you’re bullish on ContextLogic. In fact, there’s a value-added partnership in the works — along with a regulatory development that could advance the company’s geographic reach.\nA Closer Look at WISH Stock\nLet’s go back to the beginning, which actually wasn’t very long ago.\nAfter ContextLogicset a price rangeof $22 to $24 for its IPO, the company sold 46 million shares of WISH stock at $24 apiece on Dec. 15, 2020.\nEverything was off to a good start, or so it seemed. A brief rally ensued, with ContextLogic shares climbing to a 52-week high of $32.85 on Feb. 1, 2021. The situation turned sour after that, however. As it turned out, WISH stock sank during the following months, and even fell below $8 in June.\nThere might be a dip-buying opportunity here, though — and the potential for a comeback. As of July 12, the ContextLogic share price was already over $11.\nIn the interest of full disclosure, I feel compelled to reveal this: on a trailing-12-month basis, ContextLogic has -$3.16 in earnings per share. That’s not great news, but it’s not hopeless. Without a doubt, the stakeholders will want to see that number turn positive in the near future.\nA License to Sell\nThe Wish platform is supposed to be a place where shoppers on multiple continents can purchase a wide variety of products online. And judging by some recently reported data, Wish’s global e-commerce ambitions are panning out quite well.\nContextLogic reported that its Core Marketplace segment’s first-quarter 2021 revenuesincreased by 40%year-over-year. Furthermore, looking at the bigger picture, the company’s total revenues for 2021’s first quarter showed a massive 75% year-over-year improvement.\nThat alone should convince the skeptics to change their minds. Yet, there’s even more good news to share.\nOn July 6, ContextLogic revealed that the Dutch Central Bank hadgranted the companya Payment Services License for the European Union.\nApparently, this license will enable Wish to increase the company’s control over the payments value chain in a compliant manner. At the same time, it should allow Wish to reduce its reliance on third parties.\nThis has vast geographic implications, as, in addition to the Netherlands, the license “will be passported to the other European markets where Wish operates.”\nExpanding Its Reach\nOn top of all that, ContextLogic has disclosed a collaboration with another prominent e-commerce platform.\nThis could be a real game changer.\nAccording to a press release, ContextLogicannounced a two-year partnershipwithPrestaShopin which “more than 300,000 merchants and brands on the PrestaShop platform will be able to quickly and easily sell to millions of consumers on the Wish marketplace.”\nThe PrestShop platform operates in Europe and Latin America. So once again, we’re bearing witness to ContextLogic’s rapid expansion into the EU and, ultimately, around the world.\nAlan Small, senior business development manager for Wish in Europe, expressed his company’s ambitious vision with the PrestaShop partnership; “Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on,” Small explained.\nThe Bottom Line\nOkay, so WISH stock hasn’t been a blockbuster success since its IPO.\nHowever, the story hasn’t been fully written yet.\nAnd, the next few chapters could involve ContextLogic’s rapid progress — not only in the European market, but globally.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145995820,"gmtCreate":1626185337060,"gmtModify":1703755088684,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Batteries!","listText":"Batteries!","text":"Batteries!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/145995820","repostId":"2151555866","repostType":4,"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146774951,"gmtCreate":1626101552973,"gmtModify":1703753491231,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Space travel, anyone?","listText":"Space travel, anyone?","text":"Space travel, anyone?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/146774951","repostId":"1190430688","repostType":4,"repost":{"id":"1190430688","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626097090,"share":"https://www.laohu8.com/m/news/1190430688?lang=&edition=full","pubTime":"2021-07-12 21:38","market":"us","language":"en","title":"Virgin Galactic fell 6% in the morning trading, as once rising more than 10% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1190430688","media":"Tiger Newspress","summary":"Virgin Galactic fell 6% in the morning trading, as once rising more than 10% in premarket trading.\nS","content":"<p>Virgin Galactic&nbsp;fell&nbsp;6%&nbsp;in&nbsp;the&nbsp;morning&nbsp;trading,&nbsp;as&nbsp;once&nbsp;rising&nbsp;more&nbsp;than&nbsp;10%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/c4d333c87a902f8607ae09dca6c78f8c\" tg-width=\"1281\" tg-height=\"607\" referrerpolicy=\"no-referrer\">Shares of&nbsp;Virgin Galactic&nbsp;slipped on Monday after the company filed to sell up to $500 million in common stock. This follows the commercial spaceflight company’s successful test flight with founder Sir Richard Branson.</p>\n<p>Shares of Virgin Galactic — which trades under ticker SPCE — fell 8% after the $500 million in stock sale announcement that came after the company's successfully completedfully crewed test flightinto suborbital space on Sunday, a major milestone in the commercial space race and step towards the company's goal for commercial service in early 2022.</p>\n<p>The shares were last at about $44.80, after rising as much as 7% in premarket trading. The stock has doubled so far this year in anticipation of this progress toward commercial service.</p>\n<p>\"We view Branson's achievement as a massive marketing coup for Virgin Galactic that will be impossible for the public to ignore,\" Canaccord Genuity equity analyst Ken Herbert told clients. The firm has a buy rating but $35 price target on the stock, which is below its current level.</p>\n<p>The company's spacecraft VSS Unity launched above the skies of New Mexico on Sunday, with two pilots guiding the vehicle carrying the billionaire founder and three Virgin Galactic employees. VSS Unity fired its rocket engine and accelerated to faster than three times the speed of sound in a climb to the edge of space.</p>\n<p>\"We see this as important on the path toward starting passenger flights, which we assume will happen in early 2022,\" AB Bernstein analyst Douglas Harned told clients. The firm has a market perform rating on Virgin Galactic.</p>\n<p>Virgin Galactic's VSS Unity is designed to hold up to six passengers along with the two pilots. The company has about 600 reservations for tickets on future flights, sold at prices between $200,000 and $250,000 each. While passenger ticket sales have yet to be announced, Bernstein expects them to come at a higher price point between $400,000 and $500,000.</p>\n<p>Virgin Galactic also announced it is partnering with sweepstakes company Omaze to offer a chance at two seats on \"one of the first commercial Virgin Galactic spaceflights\" early next year.</p>\n<p>\"The flight is symbolically important for building consumer confidence in and demand for space tourism,\" said Harned. \"A successful test flight by Blue Origin including founder Jeff Bezos, scheduled for July 20, should generate further interest in the industry, which would benefit both companies.\"</p>\n<p><img src=\"https://static.tigerbbs.com/aaede22b48f21a26943de5199a5f26e5\" tg-width=\"740\" tg-height=\"475\" referrerpolicy=\"no-referrer\"></p>\n<p>In 2004, Branson founded Virgin Galactic to fly private passengers to space. Branson was not previously expected to fly on Sunday's spaceflight but after fellow billionaire&nbsp;Jeff Bezos&nbsp;announced&nbsp;he would fly on his company Blue Origin's first passenger flight&nbsp;on July 20, Virgin Galactic rearranged its schedule — aiming to fly Branson nine days before Bezos.</p>\n<p>Launching ahead of Bezos or&nbsp;Elon Musk, Sunday's flight means Branson is the first of the billionaire space company founders to ride his own spacecraft.</p>\n<p>AB Bernstein said the flight's success and subsequent ticket sales could well be an upward short-term catalyst for the stock but did not change their long-term forecast. The firm did note that it wouldn't be short the stock, as it has seen huge volatility driven by retail investors reacting to events.</p>\n<ul></ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Virgin Galactic fell 6% in the morning trading, as once rising more than 10% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVirgin Galactic fell 6% in the morning trading, as once rising more than 10% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-12 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Virgin Galactic&nbsp;fell&nbsp;6%&nbsp;in&nbsp;the&nbsp;morning&nbsp;trading,&nbsp;as&nbsp;once&nbsp;rising&nbsp;more&nbsp;than&nbsp;10%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/c4d333c87a902f8607ae09dca6c78f8c\" tg-width=\"1281\" tg-height=\"607\" referrerpolicy=\"no-referrer\">Shares of&nbsp;Virgin Galactic&nbsp;slipped on Monday after the company filed to sell up to $500 million in common stock. This follows the commercial spaceflight company’s successful test flight with founder Sir Richard Branson.</p>\n<p>Shares of Virgin Galactic — which trades under ticker SPCE — fell 8% after the $500 million in stock sale announcement that came after the company's successfully completedfully crewed test flightinto suborbital space on Sunday, a major milestone in the commercial space race and step towards the company's goal for commercial service in early 2022.</p>\n<p>The shares were last at about $44.80, after rising as much as 7% in premarket trading. The stock has doubled so far this year in anticipation of this progress toward commercial service.</p>\n<p>\"We view Branson's achievement as a massive marketing coup for Virgin Galactic that will be impossible for the public to ignore,\" Canaccord Genuity equity analyst Ken Herbert told clients. The firm has a buy rating but $35 price target on the stock, which is below its current level.</p>\n<p>The company's spacecraft VSS Unity launched above the skies of New Mexico on Sunday, with two pilots guiding the vehicle carrying the billionaire founder and three Virgin Galactic employees. VSS Unity fired its rocket engine and accelerated to faster than three times the speed of sound in a climb to the edge of space.</p>\n<p>\"We see this as important on the path toward starting passenger flights, which we assume will happen in early 2022,\" AB Bernstein analyst Douglas Harned told clients. The firm has a market perform rating on Virgin Galactic.</p>\n<p>Virgin Galactic's VSS Unity is designed to hold up to six passengers along with the two pilots. The company has about 600 reservations for tickets on future flights, sold at prices between $200,000 and $250,000 each. While passenger ticket sales have yet to be announced, Bernstein expects them to come at a higher price point between $400,000 and $500,000.</p>\n<p>Virgin Galactic also announced it is partnering with sweepstakes company Omaze to offer a chance at two seats on \"one of the first commercial Virgin Galactic spaceflights\" early next year.</p>\n<p>\"The flight is symbolically important for building consumer confidence in and demand for space tourism,\" said Harned. \"A successful test flight by Blue Origin including founder Jeff Bezos, scheduled for July 20, should generate further interest in the industry, which would benefit both companies.\"</p>\n<p><img src=\"https://static.tigerbbs.com/aaede22b48f21a26943de5199a5f26e5\" tg-width=\"740\" tg-height=\"475\" referrerpolicy=\"no-referrer\"></p>\n<p>In 2004, Branson founded Virgin Galactic to fly private passengers to space. Branson was not previously expected to fly on Sunday's spaceflight but after fellow billionaire&nbsp;Jeff Bezos&nbsp;announced&nbsp;he would fly on his company Blue Origin's first passenger flight&nbsp;on July 20, Virgin Galactic rearranged its schedule — aiming to fly Branson nine days before Bezos.</p>\n<p>Launching ahead of Bezos or&nbsp;Elon Musk, Sunday's flight means Branson is the first of the billionaire space company founders to ride his own spacecraft.</p>\n<p>AB Bernstein said the flight's success and subsequent ticket sales could well be an upward short-term catalyst for the stock but did not change their long-term forecast. The firm did note that it wouldn't be short the stock, as it has seen huge volatility driven by retail investors reacting to events.</p>\n<ul></ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190430688","content_text":"Virgin Galactic fell 6% in the morning trading, as once rising more than 10% in premarket trading.\nShares of Virgin Galactic slipped on Monday after the company filed to sell up to $500 million in common stock. This follows the commercial spaceflight company’s successful test flight with founder Sir Richard Branson.\nShares of Virgin Galactic — which trades under ticker SPCE — fell 8% after the $500 million in stock sale announcement that came after the company's successfully completedfully crewed test flightinto suborbital space on Sunday, a major milestone in the commercial space race and step towards the company's goal for commercial service in early 2022.\nThe shares were last at about $44.80, after rising as much as 7% in premarket trading. The stock has doubled so far this year in anticipation of this progress toward commercial service.\n\"We view Branson's achievement as a massive marketing coup for Virgin Galactic that will be impossible for the public to ignore,\" Canaccord Genuity equity analyst Ken Herbert told clients. The firm has a buy rating but $35 price target on the stock, which is below its current level.\nThe company's spacecraft VSS Unity launched above the skies of New Mexico on Sunday, with two pilots guiding the vehicle carrying the billionaire founder and three Virgin Galactic employees. VSS Unity fired its rocket engine and accelerated to faster than three times the speed of sound in a climb to the edge of space.\n\"We see this as important on the path toward starting passenger flights, which we assume will happen in early 2022,\" AB Bernstein analyst Douglas Harned told clients. The firm has a market perform rating on Virgin Galactic.\nVirgin Galactic's VSS Unity is designed to hold up to six passengers along with the two pilots. The company has about 600 reservations for tickets on future flights, sold at prices between $200,000 and $250,000 each. While passenger ticket sales have yet to be announced, Bernstein expects them to come at a higher price point between $400,000 and $500,000.\nVirgin Galactic also announced it is partnering with sweepstakes company Omaze to offer a chance at two seats on \"one of the first commercial Virgin Galactic spaceflights\" early next year.\n\"The flight is symbolically important for building consumer confidence in and demand for space tourism,\" said Harned. \"A successful test flight by Blue Origin including founder Jeff Bezos, scheduled for July 20, should generate further interest in the industry, which would benefit both companies.\"\n\nIn 2004, Branson founded Virgin Galactic to fly private passengers to space. Branson was not previously expected to fly on Sunday's spaceflight but after fellow billionaire Jeff Bezos announced he would fly on his company Blue Origin's first passenger flight on July 20, Virgin Galactic rearranged its schedule — aiming to fly Branson nine days before Bezos.\nLaunching ahead of Bezos or Elon Musk, Sunday's flight means Branson is the first of the billionaire space company founders to ride his own spacecraft.\nAB Bernstein said the flight's success and subsequent ticket sales could well be an upward short-term catalyst for the stock but did not change their long-term forecast. The firm did note that it wouldn't be short the stock, as it has seen huge volatility driven by retail investors reacting to events.","news_type":1},"isVote":1,"tweetType":1,"viewCount":134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141883828,"gmtCreate":1625846751464,"gmtModify":1703749871197,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141883828","repostId":"1155625151","repostType":4,"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141196926,"gmtCreate":1625841192565,"gmtModify":1703749692376,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/141196926","repostId":"1158342403","repostType":4,"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141196085,"gmtCreate":1625841185547,"gmtModify":1703749692213,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141196085","repostId":"1158342403","repostType":4,"repost":{"id":"1158342403","pubTimestamp":1625840608,"share":"https://www.laohu8.com/m/news/1158342403?lang=&edition=full","pubTime":"2021-07-09 22:23","market":"us","language":"en","title":"Tesla Shares Form Death Cross, Portending Further Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=1158342403","media":"Bloomberg","summary":"(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders ","content":"<p><img src=\"https://static.tigerbbs.com/bb51ddaee6b764108c6a043b0481069f\" tg-width=\"704\" tg-height=\"396\" referrerpolicy=\"no-referrer\">(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.</p>\n<p>The short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.</p>\n<p>The decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.</p>\n<p>The last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.</p>\n<p>Tesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Shares Form Death Cross, Portending Further Declines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Shares Form Death Cross, Portending Further Declines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.\nThe short-term average price for the stock fell ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/tesla-shares-form-death-cross-140046201.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158342403","content_text":"(Bloomberg) -- Tesla Inc. shares formed a trading pattern Friday that is closely watched by traders as it often precedes further losses for the stock.\nThe short-term average price for the stock fell below the long-term average, forming a so-called death cross. Shares of the electric vehicle maker have been on a rough ride already this year, falling 8%, even as the broader market rose nearly 16%.\nThe decline reflects growing investor concern about competition from traditional carmakers that are pushing aggressively into the EV race, as well as the company’s future growth trajectory in China, which is among the world’s biggest markets for automobiles. On Thursday, Tesla unveiled a significantly cheaper version of its Model Y car in the country, even as its China deliveries dropped last month.\nThe last time Tesla shares formed this trading pattern was in February 2019, and it preceded a more than 40% decline in the share price within 65 days, to $35.79 from $63.98.\nTesla shares dropped as much as 1.2% on Friday in New York. Shares of smaller EV startups also languished, with Workhorse Group Inc. and XPeng Inc. among the biggest decliners in the group.","news_type":1},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141199360,"gmtCreate":1625841059750,"gmtModify":1703749687108,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy one?","listText":"Buy one?","text":"Buy one?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141199360","repostId":"1166454239","repostType":4,"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":178171901,"gmtCreate":1626794263303,"gmtModify":1703765401659,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Why pfizer price never increase much, unlike moderna?","listText":"Why pfizer price never increase much, unlike moderna?","text":"Why pfizer price never increase much, unlike moderna?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/178171901","repostId":"2152405667","repostType":4,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141883828,"gmtCreate":1625846751464,"gmtModify":1703749871197,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141883828","repostId":"1155625151","repostType":4,"repost":{"id":"1155625151","pubTimestamp":1625845018,"share":"https://www.laohu8.com/m/news/1155625151?lang=&edition=full","pubTime":"2021-07-09 23:36","market":"us","language":"en","title":"Long-Term Prospects for Both Space Tourism and SPCE Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1155625151","media":"investorplace","summary":"Virgin Galactic(NYSE:SPCE) stock bucked the broader market selloff today, as SPCE stock surged rough","content":"<p><b>Virgin Galactic</b>(NYSE:<b><u>SPCE</u></b>) stock bucked the broader market selloff today, as SPCE stock surged roughly 20% on a day when most of Wall Street bled red. That’s quite impressive.</p>\n<p>Why is this happening?</p>\n<p>Virgin Galactic is booming becausethey’re sending Richard Branson into space on Sunday. This will be the first passenger spaceflight<i>ever</i>.</p>\n<p>This is a huge deal. Virgin has been saying it is going to fly people into space for over a decade. On Sunday, it’s going to make that long-term dream a reality. This moment, this coming weekend’s flight, is truly the culmination of 10-plus years of scientific work.</p>\n<p>And just to be clear. We very well could see a “sell the news” event on Monday. But we don’t think that will necessarily happen.</p>\n<p>Instead, we see this first commercial spaceflight as such a momentous accomplishment that it only serves to spark more buying power in SPCE stock.</p>\n<p>We’re looking for a price above $60 by next week.</p>\n<p>SPCE Stock Is a Long-Term Winner</p>\n<p>Our bullish outlook is also supported by a favorable long-term outlook on the company.</p>\n<p>We firmly believe that the space tourism industry will unlock significant economic value, and that Virgin Galactic will capitalize on this value.</p>\n<p>For one, demand for space travel will be enormous. There are a lot of rich people out there who are willing to spend next to anything for a novel experience. And flying to space is just about as novel an experience as you can find these days.</p>\n<p>Supply will be extremely limited, since only about two companies in the entire world will be able to offer commercial space tourism opportunities in the coming years.</p>\n<p>Big demand for space tourism and low supply means attractive unit economics, high margins and loads of profits.</p>\n<p>The long-term potential for space tourism is clearly here, and so is the long-term potential for Virgin Galactic.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Long-Term Prospects for Both Space Tourism and SPCE Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLong-Term Prospects for Both Space Tourism and SPCE Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 23:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/07/long-term-prospects-for-both-space-tourism-and-spce-stock/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virgin Galactic(NYSE:SPCE) stock bucked the broader market selloff today, as SPCE stock surged roughly 20% on a day when most of Wall Street bled red. That’s quite impressive.\nWhy is this happening?\n...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/07/long-term-prospects-for-both-space-tourism-and-spce-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/07/long-term-prospects-for-both-space-tourism-and-spce-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155625151","content_text":"Virgin Galactic(NYSE:SPCE) stock bucked the broader market selloff today, as SPCE stock surged roughly 20% on a day when most of Wall Street bled red. That’s quite impressive.\nWhy is this happening?\nVirgin Galactic is booming becausethey’re sending Richard Branson into space on Sunday. This will be the first passenger spaceflightever.\nThis is a huge deal. Virgin has been saying it is going to fly people into space for over a decade. On Sunday, it’s going to make that long-term dream a reality. This moment, this coming weekend’s flight, is truly the culmination of 10-plus years of scientific work.\nAnd just to be clear. We very well could see a “sell the news” event on Monday. But we don’t think that will necessarily happen.\nInstead, we see this first commercial spaceflight as such a momentous accomplishment that it only serves to spark more buying power in SPCE stock.\nWe’re looking for a price above $60 by next week.\nSPCE Stock Is a Long-Term Winner\nOur bullish outlook is also supported by a favorable long-term outlook on the company.\nWe firmly believe that the space tourism industry will unlock significant economic value, and that Virgin Galactic will capitalize on this value.\nFor one, demand for space travel will be enormous. There are a lot of rich people out there who are willing to spend next to anything for a novel experience. And flying to space is just about as novel an experience as you can find these days.\nSupply will be extremely limited, since only about two companies in the entire world will be able to offer commercial space tourism opportunities in the coming years.\nBig demand for space tourism and low supply means attractive unit economics, high margins and loads of profits.\nThe long-term potential for space tourism is clearly here, and so is the long-term potential for Virgin Galactic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802541302,"gmtCreate":1627790858006,"gmtModify":1703495936888,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Incredible! Watch and see","listText":"Incredible! Watch and see","text":"Incredible! Watch and see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/802541302","repostId":"1142925544","repostType":4,"repost":{"id":"1142925544","pubTimestamp":1627787240,"share":"https://www.laohu8.com/m/news/1142925544?lang=&edition=full","pubTime":"2021-08-01 11:07","market":"us","language":"en","title":"Investors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1142925544","media":"Barron's","summary":"“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970","content":"<p>“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970s, recalling pleasant times at the beach or by the barbecue. No need to remind anyone back then of droughts, wildfires, or Covid-19 surges that are unfortunate features of the steamy season this year.</p>\n<p>But the coming of August also means entering what historically has been the most treacherous stretch of the year for stocks, according to data going back to 1928 compiled by Bank of America analyst Stephen Suttmeier. He finds that theS&amp;P 500index had a negative return averaging 0.03% in August, September, and October—the worst three-month span of the year for the big-cap benchmark. In fact, they constitute the only three-month period that averages in the red.</p>\n<p>August actually is bracketed by the best and worst months of the year, he adds in a research note. July averages a 1.58% return on the S&amp;P 500, with positive results 59.1% of the time, while September averages a negative 1.03%, ending in the plus column less than half of the time, or 45%.</p>\n<p>This July did even better than the norm, with the S&amp;P 500 gaining 2.27%. It also was the sixth consecutive up month for the index—the longest positive streak since September 2018, according to Dow Jones’ statistical mavens. During that period, its cumulative advance was 18.34%.</p>\n<p>August’s record is in between, with an average 0.70% S&amp;P 500 return and positive results 58.1% of the time, marking a transition from the “summer rip” to the “fall dip.”</p>\n<p>Not surprisingly, the laggard returns of the August-October period are accompanied by an uptick in volatility, Suttmeier finds. Based on records going back to 1992, theCboe Volatility Index,or VIX, has often seen spikes during those months, following relatively subdued volatility in the April-July period.</p>\n<p>Past isn’t necessarily prologue, but if it is, the timing of the initial public offering byRobinhood Markets(ticker: HOOD) might prove propitious, if the stock market does have its typical seasonal rough patch. The online broker, whose putative mission is to open investing to novices supposedly ignored by established outfits, sold 55 million shares at $38 on Thursday. In the process, it provided a valuable lesson to all those who got in on the IPO: Buy low and sell high.</p>\n<p>The company evidently fulfilled the latter imperative, selling its shares high, even though they were priced at the low end of the expected $38-$42 range. Their price sank 8.4% on their first day of trading, although they recouped a bit on Friday. By week’s end, buyers of Robinhood’s IPO who held were down 7.5%.</p>\n<p>Among those who sold high were the company’s co-founders, CEO Vladimir Tenev and Chief Creative Officer Baiju Bhatt, who each offloaded 1.25 million shares in the IPO. As my illustrious predecessor, Alan Abelson, liked to observe, there are many good reasons to sell a stock, but expecting it to go up isn’t one of them. That has never been more true, given the ability of rich owners to monetize their assets by borrowing against them cheaply, and without incurring capital-gains taxes.</p>\n<p>To be sure, Tenev and Bhatt still have significant stakes in Robinhood. Asour colleague Avi Salzman reported, these were worth $2.5 billion at the initial offering price, and Tenev and Bhatt retain voting control. The two also could receive awards of shares worth as much as $6.7 billion for Tenev and $4 billion for Bhatt, if the stock hits $300, or nearly the proverbial ten-bagger from here.</p>\n<p>But in a blow against income inequality, the potential billionaire pair took symbolic pay cuts, to $34,248, the average annual wage of American workers. As the comedian Yakov Smirnoff likes to say, “What a country!”</p>\n<p>How those workers are faring will be a subject of the monthly employment report slated for release this coming Friday.</p>\n<p>Economists’ forecasts for nonfarm payrolls center around a gain of 900,000. Jefferies economists Aneta Markowska and Thomas Simons estimate that the increase could top the long-anticipated one million mark; they forecast 1.2 million.</p>\n<p>Markowska and Simons think the expiration of supplemental unemployment benefits in some states will boost the labor supply, although that is a matter of significant debate. (For more on the jobs market, seethis week’s cover story.)</p>\n<p></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors, Beware! Stocks Are Entering the Most Dangerous Stretch of the Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-01 11:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-news-robinhood-sp500-51627692215?mod=hp_LATEST><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970s, recalling pleasant times at the beach or by the barbecue. No need to remind anyone back then of ...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-news-robinhood-sp500-51627692215?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.barrons.com/articles/stocks-news-robinhood-sp500-51627692215?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142925544","content_text":"“Yes, it’s summer, my time of year,”as the group War sangin that golden oldie “Summer” from the 1970s, recalling pleasant times at the beach or by the barbecue. No need to remind anyone back then of droughts, wildfires, or Covid-19 surges that are unfortunate features of the steamy season this year.\nBut the coming of August also means entering what historically has been the most treacherous stretch of the year for stocks, according to data going back to 1928 compiled by Bank of America analyst Stephen Suttmeier. He finds that theS&P 500index had a negative return averaging 0.03% in August, September, and October—the worst three-month span of the year for the big-cap benchmark. In fact, they constitute the only three-month period that averages in the red.\nAugust actually is bracketed by the best and worst months of the year, he adds in a research note. July averages a 1.58% return on the S&P 500, with positive results 59.1% of the time, while September averages a negative 1.03%, ending in the plus column less than half of the time, or 45%.\nThis July did even better than the norm, with the S&P 500 gaining 2.27%. It also was the sixth consecutive up month for the index—the longest positive streak since September 2018, according to Dow Jones’ statistical mavens. During that period, its cumulative advance was 18.34%.\nAugust’s record is in between, with an average 0.70% S&P 500 return and positive results 58.1% of the time, marking a transition from the “summer rip” to the “fall dip.”\nNot surprisingly, the laggard returns of the August-October period are accompanied by an uptick in volatility, Suttmeier finds. Based on records going back to 1992, theCboe Volatility Index,or VIX, has often seen spikes during those months, following relatively subdued volatility in the April-July period.\nPast isn’t necessarily prologue, but if it is, the timing of the initial public offering byRobinhood Markets(ticker: HOOD) might prove propitious, if the stock market does have its typical seasonal rough patch. The online broker, whose putative mission is to open investing to novices supposedly ignored by established outfits, sold 55 million shares at $38 on Thursday. In the process, it provided a valuable lesson to all those who got in on the IPO: Buy low and sell high.\nThe company evidently fulfilled the latter imperative, selling its shares high, even though they were priced at the low end of the expected $38-$42 range. Their price sank 8.4% on their first day of trading, although they recouped a bit on Friday. By week’s end, buyers of Robinhood’s IPO who held were down 7.5%.\nAmong those who sold high were the company’s co-founders, CEO Vladimir Tenev and Chief Creative Officer Baiju Bhatt, who each offloaded 1.25 million shares in the IPO. As my illustrious predecessor, Alan Abelson, liked to observe, there are many good reasons to sell a stock, but expecting it to go up isn’t one of them. That has never been more true, given the ability of rich owners to monetize their assets by borrowing against them cheaply, and without incurring capital-gains taxes.\nTo be sure, Tenev and Bhatt still have significant stakes in Robinhood. Asour colleague Avi Salzman reported, these were worth $2.5 billion at the initial offering price, and Tenev and Bhatt retain voting control. The two also could receive awards of shares worth as much as $6.7 billion for Tenev and $4 billion for Bhatt, if the stock hits $300, or nearly the proverbial ten-bagger from here.\nBut in a blow against income inequality, the potential billionaire pair took symbolic pay cuts, to $34,248, the average annual wage of American workers. As the comedian Yakov Smirnoff likes to say, “What a country!”\nHow those workers are faring will be a subject of the monthly employment report slated for release this coming Friday.\nEconomists’ forecasts for nonfarm payrolls center around a gain of 900,000. Jefferies economists Aneta Markowska and Thomas Simons estimate that the increase could top the long-anticipated one million mark; they forecast 1.2 million.\nMarkowska and Simons think the expiration of supplemental unemployment benefits in some states will boost the labor supply, although that is a matter of significant debate. (For more on the jobs market, seethis week’s cover story.)","news_type":1},"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179226240,"gmtCreate":1626536726780,"gmtModify":1703761558606,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Uh oh is a crash coming","listText":"Uh oh is a crash coming","text":"Uh oh is a crash coming","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/179226240","repostId":"2152899486","repostType":4,"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179221805,"gmtCreate":1626536508707,"gmtModify":1703761555694,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Goody&nbsp;","listText":"Goody&nbsp;","text":"Goody","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/179221805","repostId":"2152894306","repostType":2,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LHDX":"Lucira Health, Inc.","LABP":"Landos Biopharma, Inc.","APR":"Apria, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145995820,"gmtCreate":1626185337060,"gmtModify":1703755088684,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Batteries!","listText":"Batteries!","text":"Batteries!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/145995820","repostId":"2151555866","repostType":4,"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141199360,"gmtCreate":1625841059750,"gmtModify":1703749687108,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy one?","listText":"Buy one?","text":"Buy one?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141199360","repostId":"1166454239","repostType":4,"repost":{"id":"1166454239","pubTimestamp":1625839689,"share":"https://www.laohu8.com/m/news/1166454239?lang=&edition=full","pubTime":"2021-07-09 22:08","market":"us","language":"en","title":"Tesla raises Model S and Model X prices $5,000 in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1166454239","media":"seekingalpha","summary":"After launching cheaper version of Model Y cars in China, Tesla has increased the base price of its ","content":"<ul>\n <li>After launching cheaper version of Model Y cars in China, Tesla&nbsp;has increased the base price of its redesigned Model S and Model X vehicles by $5,000 in the U.S.</li>\n <li>The Model S&nbsp;now listed with base price of $84,990 and Model X at $94,990.</li>\n <li>The car maker delivered 1,890 Model S/X vehicles and 199,360 Model 3/Y vehicles in Q2 for a total tally of 201,250.</li>\n <li>Yesterday, the companylauncheda cheaper version of the Model Y in China with a standard driving range at the starting price of ¥276,000 amid increased scrutiny from regulators.</li>\n <li>Tesla had cut its car pricesby up to $5,000 last year in May 2020for its Model S and Model X, bringing their base prices to $74,990 and $79,990&nbsp;to jump-start sales during the pandemic.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla raises Model S and Model X prices $5,000 in the U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla raises Model S and Model X prices $5,000 in the U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 22:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3713993-tesla-raises-model-s-and-model-x-prices-5000-in-the-us><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After launching cheaper version of Model Y cars in China, Tesla has increased the base price of its redesigned Model S and Model X vehicles by $5,000 in the U.S.\nThe Model S now listed with base price...</p>\n\n<a href=\"https://seekingalpha.com/news/3713993-tesla-raises-model-s-and-model-x-prices-5000-in-the-us\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://seekingalpha.com/news/3713993-tesla-raises-model-s-and-model-x-prices-5000-in-the-us","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166454239","content_text":"After launching cheaper version of Model Y cars in China, Tesla has increased the base price of its redesigned Model S and Model X vehicles by $5,000 in the U.S.\nThe Model S now listed with base price of $84,990 and Model X at $94,990.\nThe car maker delivered 1,890 Model S/X vehicles and 199,360 Model 3/Y vehicles in Q2 for a total tally of 201,250.\nYesterday, the companylauncheda cheaper version of the Model Y in China with a standard driving range at the starting price of ¥276,000 amid increased scrutiny from regulators.\nTesla had cut its car pricesby up to $5,000 last year in May 2020for its Model S and Model X, bringing their base prices to $74,990 and $79,990 to jump-start sales during the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141196926,"gmtCreate":1625841192565,"gmtModify":1703749692376,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/141196926","repostId":"1158342403","repostType":4,"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810826197,"gmtCreate":1629964672519,"gmtModify":1676530186011,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"How does Pubmatic compare with Magnite?","listText":"How does Pubmatic compare with Magnite?","text":"How does Pubmatic compare with Magnite?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810826197","repostId":"2161742695","repostType":4,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896734208,"gmtCreate":1628604826404,"gmtModify":1676529794920,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wowww","listText":"Wowww","text":"Wowww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896734208","repostId":"2158048475","repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://www.laohu8.com/m/news/2158048475?lang=&edition=full","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170786898,"gmtCreate":1626451412314,"gmtModify":1703760536573,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170786898","repostId":"1149577900","repostType":4,"isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833345858,"gmtCreate":1629208023174,"gmtModify":1676529966304,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy more on drop&nbsp;","listText":"Buy more on drop&nbsp;","text":"Buy more on drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833345858","repostId":"1113768464","repostType":2,"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896734787,"gmtCreate":1628604846549,"gmtModify":1676529794928,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Woww","listText":"Woww","text":"Woww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896734787","repostId":"2158048475","repostType":4,"repost":{"id":"2158048475","pubTimestamp":1628600160,"share":"https://www.laohu8.com/m/news/2158048475?lang=&edition=full","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144192413,"gmtCreate":1626270899732,"gmtModify":1703756786220,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to accumulate","listText":"Time to accumulate","text":"Time to accumulate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/144192413","repostId":"1164055885","repostType":2,"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141196085,"gmtCreate":1625841185547,"gmtModify":1703749692213,"author":{"id":"3565492638324481","authorId":"3565492638324481","name":"CammieBeo","avatar":"https://static.tigerbbs.com/fe9799f812f314548dfa2ceafa03ab2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Uh oh","listText":"Uh oh","text":"Uh oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141196085","repostId":"1158342403","repostType":4,"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}